ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.

By Y. Shirota, J. Stoehlmacher, Jan Brabender, Yi-ping Xiong, H. Uetake, K. Danenberg, S. Groshen, D. Tsao-Wei, P. Danenberg, H. Lenz. Journal of Clinical Oncology, 2001

662 citations recorded by the source corpus.

Subfields: Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/b8acfcd9016ed07b381b43e0c22692b9aa9e7118

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pathology and Forensic Medicine

Guido Kroemer

Citations in the corpus

Molecular mechanisms of drug resistance (2005, background): “In addition, high mRNA expression of ERCC1 and TS has been shown to be predictive of poor response to combined oxaliplatin/5-FU treatment of advanced colorectal cancer [74].”
Molecular mechanisms of cisplatin resistance (2012, background): “…with survival and/or responsiveness to cisplatin-based regimens in several human neoplasms including bladder (Bellmunt et al., 2007), colorectal (Shirota et al., 2001), gastric (Metzger et al., 1998), esophageal (Kim et al., 2008), head and neck (Handra-Luca et al., 2007; Jun et al., 2008) and…”
Apoptosis and Molecular Targeting Therapy in Cancer (2014, background): “In addition, highmRNA expression of ERCC1 and thymidin synthase (TS) has been acting as predictors for poor response to combined oxaliplatin/5FU treatment of advanced colorectal cancer [187].”
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. (2002, background): “Other studies have also reported associations between higher ERCC1 expressions and worse clinical outcomes for CDDP-based therapy for esophageal cancer (27, 28) and for oxaliplatin/5-fluorouracil treatment for colorectal cancer (29).”